Stock 300725 PHARMABLOCK SCIENCES (NANJING), INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company PharmaBlock Sciences (Nanjing), Inc.

Equities

300725

CNE1000035K5

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 27/05/2024 am IST 		5-day change 1st Jan Change
31.31 CNY +0.38% Intraday chart for PharmaBlock Sciences (Nanjing), Inc. -4.80% -20.27%
23/04 PharmaBlock Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
01/04 Tranche Update on PharmaBlock Sciences, Inc.'s Equity Buyback Plan announced on October 31, 2023. CI

Business Summary

PharmaBlock Sciences Nanjing Inc is a company mainly engaged in design, synthesis and sales of pharmaceutical molecular building blocks. The Company's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The Company is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.

Number of employees: 2,455

Sales per Business

CNY in Million2022Weight2023Weight Delta
Drug Development and Production (Contract Development and Manufacturing Organization)
48.4 %
- - 835 48.4 % -
Molecular Building Blocks (for Drug Development and Production)
31.6 %
- - 544 31.6 % -
Molecular Building Blocks (for Drug Discovery)
18.6 %
- - 321 18.6 % -
Chemical Research and Development (Chemical Research Organization)
1.4 %
- - 24 1.4 % -
Other
0.0 %
9 0.6 % 0 0.0 % -94.93%

Sales per region

CNY in Million2022Weight2023Weight Delta
Abroad
68.5 %
1,106 69.4 % 1,182 68.5 % +6.81%
China
31.5 %
489 30.6 % 544 31.5 % +11.28%

Managers

Managers TitleAgeSince
Min Min Yang CEO
 Chief Executive Officer 52 26/06/26
Yi Fei Wu DFI
 Director of Finance/CFO 45 01/21/01
Jing Wei Zhu CTO
 Chief Tech/Sci/R&D Officer 41 01/14/01
Shu Qiang Zhang BRD
 Director/Board Member 42 01/08/01
Juan Juan Wu BRD
 Director/Board Member 47 01/08/01
Jie Cai BRD
 Director/Board Member 43 01/12/01
Jin Lu IRC
 Investor Relations Contact - -

Members of the board

Members of the board TitleAgeSince
Yun Bin Gao BRD
 Director/Board Member 57 30/18/30
Min Min Yang CEO
 Chief Executive Officer 52 26/06/26
Xu Wei Zheng BRD
 Director/Board Member 60 14/19/14
Yuan Ping Jie BRD
 Director/Board Member 58 12/23/12
Jing Wei Zhu CTO
 Chief Tech/Sci/R&D Officer 41 01/14/01
Shan Bao Yu CHM
 Chairman 42 01/11/01
Jie Cai BRD
 Director/Board Member 43 01/12/01
Juan Juan Wu BRD
 Director/Board Member 47 01/08/01
Li Jin BRD
 Director/Board Member 51 29/21/29
Shu Qiang Zhang BRD
 Director/Board Member 42 01/08/01

Shareholders

NameEquities%Valuation
Min Min Yang
6.131 %
10,326,800 6.131 % 48 M ¥
Nanjing Nuowei Biotechnology Partnership LP
3.209 %
5,404,700 3.209 % 25 M ¥
Da Cheng Fund Management Co., Ltd.
2.900 %
4,885,182 2.900 % 23 M ¥
Hwabao WP Fund Management Co., Ltd.
2.865 %
4,825,248 2.865 % 22 M ¥
Hongde Fund Management Co., Ltd.
2.626 %
4,423,984 2.626 % 21 M ¥
Yinhua Fund Management Co., Ltd.
0.8676 %
1,461,431 0.8676 % 7 M ¥
Lion Fund Management Co., Ltd.
0.8542 %
1,438,840 0.8542 % 7 M ¥
GF Fund Management Co., Ltd.
0.7553 %
1,272,267 0.7553 % 6 M ¥
Zhong Ou Asset Management Co., Ltd
0.6586 %
1,109,363 0.6586 % 5 M ¥
China Merchants Fund Management Co., Ltd.
0.5995 %
1,009,796 0.5995 % 5 M ¥
NameEquities%Valuation
Min Min Yang
99.23 %
30,980,300 99.23 % 144 M ¥

Company contact information

PharmaBlock Sciences (Nanjing), Inc.

81 Huasheng Road Jiangbei New District

210032, Nanjing

+

http://www.pharmablock.com
address PharmaBlock Sciences (Nanjing), Inc.(300725)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for PharmaBlock Sciences (Nanjing), Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
31.31 CNY
Average target price
40 CNY
Spread / Average Target
+27.75%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
PHARMABLOCK SCIENCES (NANJING), INC. Stock PharmaBlock Sciences (Nanjing), Inc.
-20.27% 856M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.74% 599B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 243B
NOVARTIS AG Stock Novartis AG
+8.44% 205B
ROCHE HOLDING AG Stock Roche Holding AG
-5.97% 203B
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300725 Stock
  4. Company PharmaBlock Sciences (Nanjing), Inc.